Venture
Pear Therapeutics, Inc.
Latest Form D 2021-03-02- CIK 1615898
- State MA
- Other Health Care
- 4 Form D offerings since 2016-02-09
- Total sold
- $255M
- across 4 offerings
- Rounds
- 4
- Form D offerings since 2016-02-09
- Latest round
- $132M
- 2020-12-18 · 021-383679
- Investors
- 22
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2020-12-18 · $132M
- 2016-02-09$12.4M021-257017
- 2018-01-12$46M021-303091
- 2019-01-04$64.3M021-329643
- 2020-12-18$132M021-383679
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($132M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-383679 | First filed2020-12-18 | Latest2021-03-02 | Sought$132M | Sold$132M | Investors22 | Exemptions506(b) |
| 021-329643 | First filed2019-01-04 | Latest2019-01-04 | Sought$65M | Sold$64.3M | Investors21 | Exemptions506(b) |
| 021-303091 | First filed2018-01-12 | Latest2018-01-12 | Sought$51M | Sold$46M | Investors14 | Exemptions506(b) |
| 021-257017 | First filed2016-02-09 | Latest2016-02-09 | Sought$20.4M | Sold$12.4M | Investors13 | Exemptions506(b) |
Who backs Pear Therapeutics, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2021-03-02
| Name | Relationship | Clarification |
|---|---|---|
| Corey McCann | RelationshipExecutive Officer, Director | Clarification— |
| Andrew Schwab | RelationshipDirector | Clarification— |
| Zack Lynch | RelationshipDirector | Clarification— |
| Timothy Petersen | RelationshipDirector | Clarification— |
| Elena Viboch | RelationshipDirector | ClarificationMs. Viboch was elected as a Director subsequent to the Date of First Sale. |
| Nancy Schlichting | RelationshipDirector | ClarificationMs. Schlichting was elected as a Director subsequent to the Date of First Sale. |
| Christopher Guiffre | RelationshipExecutive Officer | Clarification— |
| Julia Strandberg | RelationshipExecutive Officer | Clarification— |
| Yuri Maricich | RelationshipExecutive Officer | Clarification— |
| Ronan O'Brien | RelationshipExecutive Officer | Clarification— |
Facts
As its latest Form D states them
- Industry
- Other Health Care
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2016-02-09
- Latest filing
- 2021-03-02
Who backs Pear Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗